Qiming Wang

9.3k total citations · 4 hit papers
189 papers, 4.1k citations indexed

About

Qiming Wang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Qiming Wang has authored 189 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Oncology, 76 papers in Pulmonary and Respiratory Medicine and 64 papers in Molecular Biology. Recurrent topics in Qiming Wang's work include Lung Cancer Treatments and Mutations (57 papers), Lung Cancer Research Studies (52 papers) and Cancer Immunotherapy and Biomarkers (17 papers). Qiming Wang is often cited by papers focused on Lung Cancer Treatments and Mutations (57 papers), Lung Cancer Research Studies (52 papers) and Cancer Immunotherapy and Biomarkers (17 papers). Qiming Wang collaborates with scholars based in China, United States and Hong Kong. Qiming Wang's co-authors include Sen Yang, Zhe Zhang, Wei Li, Yutian Pan, Pei Ma, Xi Wu, Yuan Fang, Yu Tang, Yongqian Shu and Tao Yu and has published in prestigious journals such as Journal of Biological Chemistry, Circulation and Journal of Clinical Investigation.

In The Last Decade

Qiming Wang

179 papers receiving 4.0k citations

Hit Papers

Pyroptosis: A new frontier in cancer 2019 2026 2021 2023 2019 2019 2021 2024 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pyroptosis: A new frontier in cancer
    2019 783 citations Qiming Wang et al. profile →
  2. Emerging therapies for small cell lung cancer
    2019 304 citations Qiming Wang et al. profile →
  3. MEK inhibitors for the treatment of non-small cell lung cancer
    2021 218 citations Sen Yang, Qiming Wang et al. profile →
  4. Roles of exosomes in immunotherapy for solid cancers
    2024 69 citations Zhenqiang Sun, Qiming Wang et al. Cell Death and Disease profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Qiming Wang China 29 2.1k 1.4k 1.3k 907 481 189 4.1k
Xueqiong Zhu China 35 2.2k 1.0× 957 0.7× 573 0.5× 1.0k 1.1× 511 1.1× 196 4.5k
Xishan Hao China 40 2.6k 1.2× 1.6k 1.1× 1.0k 0.8× 1.6k 1.7× 307 0.6× 150 5.1k
Yan Zhang China 36 2.2k 1.0× 953 0.7× 714 0.6× 1.1k 1.2× 328 0.7× 245 4.5k
John J. Arcaroli United States 35 1.9k 0.9× 1.3k 0.9× 945 0.7× 1.0k 1.1× 582 1.2× 76 5.0k
Natasha Kyprianou United States 37 2.7k 1.3× 1.3k 0.9× 1.8k 1.4× 981 1.1× 227 0.5× 106 5.0k
Jasper L.A. Vleugels Netherlands 13 1.4k 0.7× 1.9k 1.3× 909 0.7× 940 1.0× 233 0.5× 27 3.7k
Cristóbal Belda-Iniesta Spain 30 2.9k 1.4× 1.3k 1.0× 684 0.5× 1.4k 1.5× 229 0.5× 104 4.8k
Wolfgang Hilbe Austria 33 1.2k 0.6× 1.3k 0.9× 794 0.6× 448 0.5× 361 0.8× 129 3.9k

Countries citing papers authored by Qiming Wang

Since Specialization
Citations

This map shows the geographic impact of Qiming Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qiming Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qiming Wang more than expected).

Fields of papers citing papers by Qiming Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qiming Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qiming Wang. The network helps show where Qiming Wang may publish in the future.

Co-authorship network of co-authors of Qiming Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Qiming Wang. A scholar is included among the top collaborators of Qiming Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qiming Wang. Qiming Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pan, Yan, et al.. (2025). Regulatory T cells in solid tumor immunotherapy: effect, mechanism and clinical application. Cell Death and Disease. 16(1). 277–277. 10 indexed citations
2.
Cheng, Ying, Jie Wang, Yan Yu, et al.. (2025). Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer. Clinical Cancer Research. 31(14). 2926–2934. 1 indexed citations
3.
Yu, Jia, Caicun Zhou, Kai Wang, et al.. (2024). Mefatinib as first-line treatment of EGFR sensitizing mutation-positive non-small-cell lung cancer: A phase III efficacy and biomarker study.. Journal of Clinical Oncology. 42(16_suppl). 8546–8546.
4.
Chen, Haiyang, Yufeng Wu, Shuxiang Ma, et al.. (2024). High-dose furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study.. Journal of Clinical Oncology. 42(16_suppl). 8587–8587. 1 indexed citations
5.
Wang, Jie, Jianchun Duan, Yuping Sun, et al.. (2024). ARTEMIS-001: Data from a phase 1a/b study of HS-20093 in patients with relapsed small cell lung cancer (SCLC).. Journal of Clinical Oncology. 42(16_suppl). 8093–8093. 10 indexed citations
6.
7.
Huang, Yan, Qitao Yu, Nong Yang, et al.. (2023). Tislelizumab plus chemotherapy in patients with advanced brain metastases of non-squamous non-small cell lung cancer: A multicenter, prospective, open-label phase 2 study.. Journal of Clinical Oncology. 41(16_suppl). 9080–9080. 2 indexed citations
8.
Qin, Shukui, Ying Cheng, Lihua Wu, et al.. (2023). First-in-human study of ZG005, a dual specific antibody targeting TIGIT and PD-1, as monotherapy in patients with advanced solid tumors.. Journal of Clinical Oncology. 41(16_suppl). e14504–e14504. 1 indexed citations
9.
Zhang, Wei, Jing Wang, Qiming Wang, et al.. (2023). A randomized double-blind trial of TQB2450 with or without anlotinib in pretreated driver-negative non-small cell lung cancer. Lung Cancer. 184. 107353–107353. 7 indexed citations
10.
Wang, Yan, et al.. (2022). Efficacy and safety of olaparib in the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review and meta-analysis. European Journal of Gynaecological Oncology. 43(3). 46–46. 1 indexed citations
11.
Zhu, Lei, Zhen Chen, Hongjing Zang, et al.. (2021). Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib. Cancer Research. 81(18). 4822–4834. 50 indexed citations
12.
Qian, Guoqing, Jianping Guo, C. Hu, et al.. (2021). Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors. Molecular Cancer Research. 19(10). 1622–1634. 34 indexed citations
13.
Liu, Ying, Ying Cheng, Qiming Wang, et al.. (2021). Effectiveness of anlotinib in patients with small‐cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study. Thoracic Cancer. 12(22). 3039–3045. 8 indexed citations
14.
Cheng, Ying, Qiming Wang, Kai Li, et al.. (2021). Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial. Cancer Medicine. 11(4). 1081–1087. 15 indexed citations
15.
Cheng, Ying, Qiming Wang, Kai Li, et al.. (2021). Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study. British Journal of Cancer. 125(3). 366–371. 103 indexed citations
16.
Yu, De‐Quan, et al.. (2021). Breast Cancer Subtypes and Mortality of Breast Cancer Patients With Brain Metastasis at Diagnosis: A Population-Based Study. INQUIRY The Journal of Health Care Organization Provision and Financing. 58. 2846649364–2846649364. 4 indexed citations
17.
18.
Wang, Liya, Xiujie Sheng, Qiming Wang, et al.. (2020). <p>Malignant Ovarian Tumors During Pregnancy: A Multicenter Retrospective Analysis</p>. Cancer Management and Research. Volume 12. 10841–10848. 7 indexed citations
19.
Wang, Qiming, et al.. (2013). Comparison of Expression of Growth Hormone-Releasing Hormone and Its Receptor Splice Variant 1 in Different Stages of Endometriosis. SHILAP Revista de lepidopterología.
20.
Wang, Qiming, et al.. (2006). Relationship between CYP2C9 and GST M1 Genetic Polymorphism and Lung Cancer Susceptibility. Zhongliu fangzhi yanjiu. 33(1). 8–10. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xueqiong Zhu Breakdown of academic impact, for papers by Xishan Hao Breakdown of academic impact, for papers by Yan Zhang Breakdown of academic impact, for papers by John J. Arcaroli Breakdown of academic impact, for papers by Natasha Kyprianou Breakdown of academic impact, for papers by Jasper L.A. Vleugels Breakdown of academic impact, for papers by Cristóbal Belda-Iniesta Breakdown of academic impact, for papers by Wolfgang Hilbe
Rankless by CCL
2026